1. Home
  2. LEGN vs CIEN Comparison

LEGN vs CIEN Comparison

Compare LEGN & CIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • CIEN
  • Stock Information
  • Founded
  • LEGN 2014
  • CIEN 1992
  • Country
  • LEGN United States
  • CIEN United States
  • Employees
  • LEGN N/A
  • CIEN N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • CIEN Telecommunications Equipment
  • Sector
  • LEGN Health Care
  • CIEN Utilities
  • Exchange
  • LEGN Nasdaq
  • CIEN Nasdaq
  • Market Cap
  • LEGN 5.4B
  • CIEN 10.2B
  • IPO Year
  • LEGN 2020
  • CIEN 1997
  • Fundamental
  • Price
  • LEGN $38.96
  • CIEN $77.91
  • Analyst Decision
  • LEGN Strong Buy
  • CIEN Buy
  • Analyst Count
  • LEGN 12
  • CIEN 14
  • Target Price
  • LEGN $73.91
  • CIEN $82.62
  • AVG Volume (30 Days)
  • LEGN 1.6M
  • CIEN 2.1M
  • Earning Date
  • LEGN 08-08-2025
  • CIEN 09-03-2025
  • Dividend Yield
  • LEGN N/A
  • CIEN N/A
  • EPS Growth
  • LEGN N/A
  • CIEN N/A
  • EPS
  • LEGN N/A
  • CIEN 0.73
  • Revenue
  • LEGN $728,303,000.00
  • CIEN $4,264,558,000.00
  • Revenue This Year
  • LEGN $65.49
  • CIEN $16.34
  • Revenue Next Year
  • LEGN $53.76
  • CIEN $9.74
  • P/E Ratio
  • LEGN N/A
  • CIEN $106.51
  • Revenue Growth
  • LEGN 112.46
  • CIEN 2.86
  • 52 Week Low
  • LEGN $27.34
  • CIEN $44.89
  • 52 Week High
  • LEGN $60.87
  • CIEN $101.44
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 66.26
  • CIEN 48.91
  • Support Level
  • LEGN $34.64
  • CIEN $77.11
  • Resistance Level
  • LEGN $39.88
  • CIEN $81.84
  • Average True Range (ATR)
  • LEGN 1.46
  • CIEN 2.17
  • MACD
  • LEGN 0.37
  • CIEN -0.21
  • Stochastic Oscillator
  • LEGN 87.67
  • CIEN 41.83

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CIEN Ciena Corporation

Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.

Share on Social Networks: